Heart Failure Guideline Directed Medical Therapy: Which One and When?  

作　　者：Michelle Dimza Juan M.Aranda Jr. 

机构地区：[1]Division of Cardiovascular Medicine,University of Florida College of Medicine,Gainesville,Florida

出　　处：《Cardiovascular Innovations and Applications》2023年第1期699-702,共4页心血管创新与应用(英文)

摘　　要：Over the past several decades,major strides have been made in the management of heart failure with reduced ejection fraction(HFrEF).The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with symptomatic HFrEF[1].This guideline directed therapy(GDMT)includes renin angiotensin receptor(RAAS)blockade,preferentially with angiotensin receptor neprilysin inhibitors(ARNI),beta blockers,mineralocorticoid receptor antagonists(MRA),and sodium-glucose cotransporter inhibitors(SGLT2i).

关 键 词：drug classes guideline directed therapy gdmt includes heart failure renin angiotensin receptor raas blockadepreferentially 

分 类 号：R541.6[医药卫生—心血管疾病]